AFFF Lawsuit Timeline: How the Federal PFAS Litigation Reached Its Current Stage

2018-2022: one court takes on a many-sided PFAS dispute

On December 7, 2018, the Judicial Panel on Multidistrict Litigation centralized federal lawsuits involving aqueous film-forming foam in the District of South Carolina. The cases shared allegations that fluorinated foams used at airports, military sites, fire-training facilities, and industrial locations released PFAS into the environment. Judge Richard M. Gergel was assigned coordinated discovery and pretrial management. The transfer order was procedural: it did not establish that any defendant made a defective product, that a particular exposure occurred, or that PFAS caused a particular person's disease.

The court then had to organize claims that looked similar at a distance but demanded different evidence. Public water systems alleged costs associated with testing and treating drinking water. Individuals alleged cancers or other injuries after occupational or residential exposure. Property owners and sovereign entities asserted still other harms. Early case-management orders separated these tracks, created discovery procedures, and selected representative issues. That separation remains the key to reading every later headline about the AFFF litigation.

2023-2024: water settlements advance while personal-injury cases are selected

In 2023, the court approved administration steps for proposed settlements involving certain public water systems and defendants including 3M and DuPont-related entities. Those agreements were built around defined water-provider classes, testing results, contamination pathways, releases, and claims-administration rules. They were not settlements of a firefighter's cancer claim. Final-approval orders and settlement documents should be read for the exact class definition; a large gross fund figure does not translate into an individual medical-injury value.

At the same time, the court developed a personal-injury bellwether pool through the Case Management Order 26 series. A May 7, 2024 order described 25 plaintiffs associated with two exposure sites and four primary alleged injuries: kidney cancer, testicular cancer, thyroid disease, and ulcerative colitis. Bellwether selection allows focused fact and expert discovery. It does not mean the court has accepted those diagnoses as caused by AFFF, and it does not bar defendants from contesting product identification, dose, latency, alternative causes, or legal responsibility.

2024-2025: regulation changes the background, not the burden of proof

EPA published a national primary drinking-water regulation for six PFAS on April 26, 2024, including enforceable limits for PFOA and PFOS. The rule matters to utilities and provides a regulatory benchmark for drinking water. It is not a judicial finding about past AFFF exposure, and exceeding a water limit does not by itself prove that one person's illness was caused by a defendant's foam. Environmental regulation and tort causation answer different questions with different evidence.

In August 2025, Case Management Order 35 vacated an October 2025 personal-injury bellwether date while the court confronted a large inventory of filed and unfiled claims and imposed more structured vetting requirements. CMO 36 addressed pleading and transfer issues involving alleged PFAS exposure through drinking water, direct AFFF contact, turnout gear, or other products. These orders show active docket management, not a collapsed litigation or a courtwide personal-injury settlement.

2026: expert work continues in the personal-injury track

Case Management Order 26.N, filed March 17, 2026, moved additional Group B personal-injury plaintiffs forward and required proposals concerning expert discovery by July 20, 2026. Expert discovery is where parties develop and challenge opinions about general causation, specific exposure, dose, diagnosis, and alternative explanations. A case entering that phase has not won, qualified for payment, or been selected as a final trial case. It has advanced within a court-designed sample.

JPML's July 1, 2026 report supplies the best standardized count of federal actions, but it should be treated as a snapshot. A pending total changes when cases are filed, transferred, dismissed, remanded, or resolved. The report does not count every potential claimant and does not label how each action left the docket. For current status, use the monthly JPML report together with the South Carolina court's dated orders, never an undated search-result summary.

How to use this timeline without overreading it

A reader evaluating a personal history should build a separate chronology: dates and locations of foam use or contaminated-water exposure; job duties and protective practices; product or site records; PFAS testing, if any; symptom onset; diagnosis; and treatment. Exposure to the PFAS family is not interchangeable with proof of exposure to a defendant's AFFF. A blood result can document measured PFAS at one time, but it generally cannot identify a manufacturer or independently prove the source and timing of exposure.

The official timeline does not provide a universal filing deadline or award schedule. Limitations rules can depend on state law, discovery of injury, exposure history, and claims pleaded. Medical decisions should remain with treating clinicians, and no one should stop screening or treatment because of litigation news. The most defensible status as of July 10, 2026 is simple: water-provider resolutions are being administered, personal-injury bellwether development continues, and individual outcomes remain unproven and case specific.

Reader questions

Frequently asked questions